Saito H - Search Results

1

Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti-PD-1 inhibitor.

Matsuo N, Azuma K, Hattori S, Ohtake J, Kawahara A, Ishii H, Tokito T, Yamada K, Shibata Y, Shimokawaji T, Kondo T, Kato T, Saito H, Yamada K, Sasada T, Hoshino T. Matsuo N, et al. Among authors: saito h. Int J Cancer. 2019 Mar 1;144(5):1170-1179. doi: 10.1002/ijc.31923. Epub 2018 Nov 12. Int J Cancer. 2019. PMID: 30307035

2

Expression of vascular endothelial growth factor and basic fibroblast growth factor in small adenocarcinomas.

Ito H, Oshita F, Kameda Y, Suzuki R, Ikehara M, Arai H, Mitsuda A, Saito H, Yamada K, Noda K, Nakayama H. Ito H, et al. Among authors: saito h. Oncol Rep. 2002 Jan-Feb;9(1):119-23. Oncol Rep. 2002. PMID: 11748468

3

Expression of survivin correlated with vessel invasion is a marker of poor prognosis in small adenocarcinoma of the lung.

Ikehara M, Oshita F, Kameda Y, Ito H, Ohgane N, Suzuki R, Saito H, Yamada K, Noda K, Mitsuda A. Ikehara M, et al. Among authors: saito h. Oncol Rep. 2002 Jul-Aug;9(4):835-8. Oncol Rep. 2002. PMID: 12066218

4

Detection of occult tumor cells in peripheral blood from patients with small cell lung cancer by promoter methylation and silencing of the retinoic acid receptor-beta.

Oshita F, Sekiyama A, Suzuki R, Ikehara M, Yamada K, Saito H, Noda K, Miyagi Y. Oshita F, et al. Among authors: saito h. Oncol Rep. 2003 Jan-Feb;10(1):105-8. Oncol Rep. 2003. PMID: 12469153

5

Expression of cyclin D1 but not of cyclin E is an indicator of poor prognosis in small adenocarcinomas of the lung.

Ikehara M, Oshita F, Ito H, Ohgane N, Suzuki R, Saito H, Yamada K, Noda K, Mitsuda A, Kameda Y. Ikehara M, et al. Among authors: saito h. Oncol Rep. 2003 Jan-Feb;10(1):137-9. Oncol Rep. 2003. PMID: 12469159

6

Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer.

Oshita F, Yamada K, Kato Y, Ikehara M, Noda K, Tanaka G, Nomura I, Suzuki R, Saito H. Oshita F, et al. Among authors: saito h. Cancer Chemother Pharmacol. 2003 Jul;52(1):73-8. doi: 10.1007/s00280-003-0615-y. Epub 2003 May 16. Cancer Chemother Pharmacol. 2003. PMID: 12750839 Clinical Trial.

7

Genome-wide cDNA microarray screening to correlate gene expression profile with survival in patients with advanced lung cancer.

Ikehara M, Oshita F, Sekiyama A, Hamanaka N, Saito H, Yamada K, Noda K, Kameda Y, Miyagi Y. Ikehara M, et al. Among authors: saito h. Oncol Rep. 2004 May;11(5):1041-4. Oncol Rep. 2004. PMID: 15069544

8

High expression of integrin beta1 and p53 is a greater poor prognostic factor than clinical stage in small-cell lung cancer.

Oshita F, Kameda Y, Hamanaka N, Saito H, Yamada K, Noda K, Mitsuda A. Oshita F, et al. Among authors: saito h. Am J Clin Oncol. 2004 Jun;27(3):215-9. doi: 10.1097/01.coc.0000054894.64867.80. Am J Clin Oncol. 2004. PMID: 15170136

9

Prognostic impact of survivin, cyclin D1, integrin beta1, and VEGF in patients with small adenocarcinoma of stage I lung cancer.

Oshita F, Ito H, Ikehara M, Ohgane N, Hamanaka N, Nakayama H, Saito H, Yamada K, Noda K, Mitsuda A, Kameda Y. Oshita F, et al. Among authors: saito h. Am J Clin Oncol. 2004 Aug;27(4):425-8. doi: 10.1097/01.coc.0000128864.15609.5b. Am J Clin Oncol. 2004. PMID: 15289739

10

Genomic-wide cDNA microarray screening to correlate gene expression profile with chemoresistance in patients with advanced lung cancer.

Oshita F, Ikehara M, Sekiyama A, Hamanaka N, Saito H, Yamada K, Noda K, Kameda Y, Miyagi Y. Oshita F, et al. Among authors: saito h. J Exp Ther Oncol. 2004 Jul;4(2):155-60. J Exp Ther Oncol. 2004. PMID: 15500010

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8,654 results

Search Page

Filters